Marathon Capital Management’s ADMA Biologics ADMA Stock Holding History

Marathon Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.46M	Sell	532,353 -95,035	-15%	-$866K	0.9%	37
2026 Q1	$5.65M	Buy	627,388 +162,073	+35%	+$2.56M	1.27%	25
2025 Q4	$8.49M	Sell	465,315 -1,255	-0.3%	-$21.2K	1.83%	14
2025 Q3	$6.84M	Buy	466,570 +182,880	+64%	+$3.13M	1.57%	18
2025 Q2	$5.17M	Buy	283,690 +128,570	+83%	+$2.62M	1.32%	22
2025 Q1	$3.08M	Buy	+155,120	New	+$2.68M	0.82%	37

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marathon Capital Management's ADMA Position: Q2 2026 in Review

Marathon Capital Management reduced its ADMA Biologics (ADMA) stake by 15% in Q2 2026, selling an estimated $866K and leaving 532,353 shares worth $4.46M. The position accounts for 0.9% of the portfolio, ranked #37.

Marathon Capital Management first reported a position in ADMA in Q1 2025 and has held it in 6 quarters since. The position peaked at $8.49M in Q4 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Marathon Capital Management held 532,353 shares of ADMA Biologics worth $4.46M as of Q2 2026.
Marathon Capital Management sold 95,035 ADMA Biologics shares in Q2 2026, an estimated $866K.
ADMA Biologics made up 0.9% of Marathon Capital Management's portfolio in Q2 2026, its #37 holding.
Marathon Capital Management first reported a position in ADMA Biologics in Q1 2025 and has held it in 6 quarters since.
Marathon Capital Management's ADMA Biologics position peaked at $8.49M in Q4 2025.
323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Marathon Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.